SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-19-001644
Filing Date
2019-08-14
Accepted
2019-08-14 15:41:05
Documents
43
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymx_6k.htm 6-K 8633
2 EX-99.1 nymx_ex991.htm EX-99.1 252547
3 EX-99.2 nymx_ex992.htm EX-99.2 11128
4 EX-99.3 nymx_ex993.htm EX-99.3 11031
11 nymx_ex991img2.jpg GRAPHIC 13498
  Complete submission text file 0001640334-19-001644.txt   1750234

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nymx-20190630.xml EX-101.INS 330618
6 XBRL TAXONOMY EXTENSION SCHEMA nymx-20190630.xsd EX-101.SCH 49558
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20190630_cal.xml EX-101.CAL 28317
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20190630_def.xml EX-101.DEF 55077
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20190630_lab.xml EX-101.LAB 146442
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20190630_pre.xml EX-101.PRE 113580
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 191025850
SIC: 2835 In Vitro & In Vivo Diagnostic Substances